Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Asco 2021 – the exon 20 army lines up behind Rybrevant
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Covid-19 stalls biotech flotations
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
